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Abstract
Background: Influenza infections have been associated with procoagulant changes. Whether
influenza infections lead to an increased risk of pulmonary embolism remains to be established.
Methods: We conducted a nested case control study in a large cohort of patients with a clinical
suspicion of having pulmonary embolism. Blood samples were collected to investigate the presence
of influenza A and B by complement fixation assay (CFA). We compared case patients, in whom
pulmonary embolism was proven (n = 102), to controls, in whom pulmonary embolism was
excluded (n = 395). Furthermore, we compared symptoms of influenza-like illness in both patient
groups 2 weeks prior to inclusion in the study, using the influenza-like illness (ILI) score, which is
based on a questionnaire. We calculated the risk of pulmonary embolism associated with influenza
infection.
Results: The percentage of patients with influenza A was higher in the control group compared to
the case group (4.3% versus 1.0%, respectively, odds ratio 0.22; 95% CI: 0.03–1.72). Influenza B was
not detectable in any of the cases and was found in 3 of the 395 controls (0.8%). The ILI score was
positive in 24% of the cases and 25% in the control persons (odds ratio 1.16, 95% CI: 0.67–2.01).
We did not observe an association between the ILI score and proven influenza infection.
Conclusion: In this clinical study, influenza infection was not associated with an increased risk of
acute pulmonary embolism. The ILI score is non-specific in this clinical setting.
Background
Deep vein thrombosis and pulmonary embolism, collec-
tively known as venous thromboembolism (VTE), have
an annual incidence of approximately 2–3 per 1000 peo-
ple [1]. Many risk factors of venous thromboembolism
have been well established, including genetic predisposi-
tion, immobilization, surgery, pregnancy, oral contracep-
tives and malignancies. However, there are patients who
develop venous thromboembolism in the absence of one
of these risk factors. There is growing evidence that acute
infections are associated with an increased risk of develop-
ing a venous thromboembolic event.
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Emmerich and others found an association between posi-
tive antibody titers for Chlamydia pneumoniae and
venous thromboembolism [2-4]. Also, patients with HIV
are at increased risk of developing venous thromboembo-
lism [5]. In a population-based case-control study, sub-
jects with elevated IL-8 levels had an increased risk of
venous thrombosis, which indicates the role of inflamma-
tion (potentially as a consequence of infection) in the
pathogenesis of venous thrombosis [6].
Recently, it has been observed that acute urinary tract
infection and signs of respiratory tract infection are asso-
ciated with an increased the risk of venous thromboembo-
lism [7]. The risk was highest during the 2 weeks after a
urinary tract infection, with an incidence ratio for deep
vein thrombosis of 2.10 (95% CI 1.56–2.82), and that for
PE of 2.11 (1.38–3.23), and gradually falling over the sub-
sequent months. The incidence ratio for deep vein throm-
bosis in patients with signs of a respiratory tract infection
was 1.91 (95% CI: 1.49–2.44). Possible diagnostic mis-
classification of an early presentation of PE as a respira-
tory infection precluded a reliable estimate of the risk of
PE after respiratory tract infection.
It is known since Virchov that venous thromboembolism
is usually the result of either a procoagulant state of the
blood, or dysfunction of the vessel wall, eventually in
combination with reduced flow of the blood. It has been
shown in vitro that influenza affects each of these factors.
Visseren et al. demonstrated that monocytes and endothe-
lial cells that were incubated with influenza are able to
activate coagulation, causing an average 55% reduction in
clotting time and a 4- to 5-fold increase in the expression
of tissue factor [8,9]. There are also indications that influ-
enza leads to a procoagulant state of the blood in vivo.
Recently, we have shown that influenza infections in eld-
erly people result in increased levels of the prohemostatic
proteins von Willebrand factor and plasmin-α2-antiplas-
min (PAP) [10]. It is further known that inflammation
leads to down regulation of thrombomodulin and the
endothelial cell protein C receptor (EPCR) via different
cytokines, thereby reducing the ability to generate the nat-
ural anticoagulant activated protein C (APC). Further-
more, inflammation induces inhibition of fibrinolysis by
elevated levels of plasminogen activator inhibitor 1 (PAI-
1), and via inflammatory mediators like interleukin 6 it
increases the number of platelets and the newly formed
thrombocytes appear to be more thrombogenic [11].
There are few data on the possible association between
acute respiratory tract infections caused by influenza virus
and the occurrence of venous thromboembolism. We
hypothesized that influenza infections lead to a pro-coag-
ulant state of the blood, resulting in a higher risk of pul-
monary embolism. Therefore, we assessed the frequency
of influenza infection among patients with a clinical sus-
picion of acute pulmonary embolism. Furthermore, we
established whether the presence of signs and symptoms
of an acute influenza-like illness (ILI) are specific in the
clinical setting of patients suspect for having acute pulmo-
nary embolism.
Methods
Study design
We performed a nested case control study in the cohort of
the ANTELOPE study. The ANTELOPE study was per-
formed from May 1999 to April 2001 in three hospitals in
the Netherlands, as described in more detail previously
[12]. In this study, in- and outpatients, with clinically sus-
pected acute pulmonary embolism, were prospectively
investigated. The diagnosis of pulmonary embolism was
confirmed by a high probability perfusion-ventilation (V/
Q) scan.
From this cohort we selected case patients, in whom pul-
monary embolism was proven and we compared them to
controls from the same cohort, in whom pulmonary
embolism was excluded.
Laboratory investigations
Blood samples were taken on the day of inclusion in the
ANTELOPE study. Follow-up samples were taken 2–3
weeks later (convalescent phase). Influenza detection in
serum samples was performed by a complement fixation
assay (CFA). A recent influenza infection is suggested by a
fourfold rise in complement fixation titre in paired sam-
ples or by a single high titre [13]. Therefore, a dilution of
1:64 or more was considered to be highly suggestive for
recent influenza A and/or B infection and regarded as a
positive test result.
Influenza-like illness
At baseline we recorded symptoms of a respiratory tract
infection, including: acute onset of fever (temperature ≥
37,8°C), subjective feeling of fever or chills, cough with or
without sputum, rhinitis, headache and sore throat. From
these symptoms an influenza-like illness (ILI) score was
calculated, based on the recommendations of previous
studies on clinical signs and symptoms predicting influ-
enza infection [14,15]. The ILI score was considered posi-
tive when there was an acute onset of fever (> 37.8°C)
plus at least two of the above mentioned symptoms two
weeks or less prior to inclusion.
Statistical analysis
Results are presented as means plus or minus standard
deviation (SD) and in percentages. Odds ratios (OR) and
corresponding 95% confidence intervals (95% CI), to
indicate the association between influenza infection and
pulmonary embolism, were calculated using logisticThrombosis Journal 2007, 5:16 http://www.thrombosisjournal.com/content/5/1/16
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regression analysis. Odds ratios were adjusted for age,
chronic obstructive pulmonary disease (COPD) and
asthma.
Results
In this study a total of 497 patients were included, 102
patients with an acute pulmonary embolism and 395
patients in which a pulmonary embolism was excluded.
Baseline characteristics of the pulmonary embolism group
and non-pulmonary embolism group are shown in table
1.
Number of influenza infections
The percentage of patients with a positive result of the CFA
for influenza A was higher in the non-pulmonary embo-
lism group (17/395 (4.3%)) compared to the pulmonary
embolism group (1/102 (1.0%)). The odds ratio was 0.22;
95% CI: 0.03–1.72. Influenza B was not detectable in any
of the pulmonary embolism patients and in 3 of the 395
non-pulmonary embolism patients (0.8%). We did not
calculate the odds ratio for influenza B, because of this
very low number of patients with influenza B.
Vaccination has not been recorded in this study. In the
Netherlands, patients are considered for vaccination
against influenza from the age of 65 (on a voluntary
basis), or when they belong to certain risk groups, such as
patients with COPD or cardiovascular disease. From the
pulmonary embolism group, 39 subjects (38%) were
older than 65 years versus 103 subjects (26%) in the con-
trol group. The frequency of subjects that belong to such a
risk group was higher in the control group (COPD 4,9%
versus 10.6% and atherosclerotic disease 9.8% versus
11.9% in the cases and controls respectively).
Symptoms of respiratory tract infection
The influenza-like illness score was positive in 24% of the
pulmonary embolism patients (24/102). In the non-pul-
monary embolism group this was the case for 25% (99/
395). The adjusted odds ratio for the influenza-like illness
score was 1.16; 95% CI: 0.67–2.01. We did not observe a
clear association between the influenza-like illness score
and proven influenza detection by CFA in either group.
Discussion
In this case control study we assessed the frequency of
influenza in a cohort of patients with a clinical suspicion
of pulmonary embolism and demonstrate that influenza
A infection is rare among patients with a proven pulmo-
nary embolism, while it does occur significantly more
often in the group of patients without pulmonary embo-
lism. Symptoms of influenza, detected by the influenza-
like illness score, were frequently present in both patient
groups. Therefore, we could not establish an association
between influenza, which causes respiratory tract infec-
tions, and an increased risk of pulmonary embolism. Our
results indicate that influenza is not an important preced-
ing factor for pulmonary embolism and that symptoms of
influenza are non-specific in this clinical context. It could
also indicate that influenza is only one of the possible
pathogens causing an acute respiratory infection and that
other pathogens, which we did not study, may play a role.
Table 1: Baseline characteristics.
Baseline characteristics
Case Group (n = 102) Control Group (n = 395)
Sex:
Male 46 (45.1%) 139 (35.2%)
Female 56 (54.9%) 216 (54.7%)
Age 58 (SD 17.1) 53 (SD17.6)
COPD 5 (4.9%) 42 (10.6%)
Asthma 5 (4.9%) 38 (9.6%)
Atherosclerotic disease 10 (9.8%) 47 (11.9%)
Malignancy 23 (22.5%) 54 (13.7%)
Immobilisation 16 (15.7%) 42 (10.6%)
Recent surgery 20 (19.0%) 56 (14.2%)
Recent trauma 2 (2.0%) 4 (1.0%)
Oral anticonceptives 12 (11.8%) 47 (11.9%)
History of VTE 19 (18.6%) 35 (8.9%)
Family history of CVD 15 (14.7%) 40 (10.1%)
Smoking 11 (10.8%) 74 (18.7%)
Baseline characteristics of pulmonary embolism group versus non-pulmonary embolism group: frequencies with Standard Deviation (SD) and 
percentages between brackets. Immobilisation: complete immobilisation for at least 3 days during the 4 weeks prior to inclusion. COPD: Chronic 
Obstructive Pulmonary Disease. CVD = Cardio Vascular Disease. VTE = venous thromboembolismThrombosis Journal 2007, 5:16 http://www.thrombosisjournal.com/content/5/1/16
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It is conceivable that influenza infections do occur more
often in our control patients, since respiratory tract infec-
tions can cause a clinical picture that may be very similar
to that of a pulmonary embolism. In fact, respiratory tract
infection is one of the more common alternative diag-
noses among patients suspected of having a pulmonary
embolism [16].
Some aspects of the study require comment. First, for
influenza detection we only used serum samples for the
detection of viruses. Although the use of the complement
binding assay makes false positive tests highly unlikely,
for a more thorough detection, influenza genome detec-
tion in throat swabs or even nasal washes is preferred in
combination with serum detection [17]. Furthermore,
baseline serum samples have been collected at the time of
admission to the hospital. If the influenza infection has
occurred 1–2 weeks prior to admission, the antibodies
may have already had peaked and a fourfold rise may not
have been detected.
Secondly, the differences in patient characteristics
between the two groups may have influenced the out-
come. Since the effects of these differences are in opposite
directions, we do not expect that the net effect has a major
influence on the outcome of this study. Mean age in the
patients with pulmonary embolism is slightly higher than
in those without (58 vs. 53 years, respectively) and age is
related with susceptibility for infection. The prevalence of
asthma and COPD, which are also associated with suscep-
tibility for influenza, was lower among the patients with
pulmonary embolism. The degree of vaccination against
influenza was not recorded in this study. Therefore we can
not exclude whether there were less vaccinated subjects in
the control group compared to the pulmonary embolism
group, which could explain the difference in frequency of
influenza infection. However, we expect that the degree of
vaccination will be similar in both groups, based on the
age distribution and numbers of subjects with a higher
risk of influenza (as described in the results section).
Therefore we conclude that vaccination against influenza
probably does not significantly contribute to the differ-
ences in the frequency of infection with influenza. We
adjusted the crude odds ratios for the following con-
founding factors: age, COPD and asthma. The adjusted
odds ratios did not differ from the crude odds ratios (table
2).
Since we compared our patients with pulmonary embo-
lism to patients with symptoms of chest pain and/or dys-
pnoea, and not to a control group of randomly selected
individuals, we still can not exclude the possibility that
influenza leads to an increased risk of venous throm-
boembolism. However, the low rate of the very common
influenza infection in the pulmonary embolism group, 1
out of 102 (1.0%), indicates that if this would be the case,
this risk is probably only marginally increased. A large
scaled study is needed to solve this issue.
We observed that the percentage of positive ILI scores was
more or less the same in both patient groups, while the
number of influenza infections was lower in the pulmo-
nary embolism group. Influenza-like illness scores similar
to our score are used in population based studies on res-
piratory tract infection and vaccination studies, in which
the incidence of pulmonary embolism is low. Our results
demonstrate that an influenza-like illness questionnaire,
and thus symptoms of respiratory tract infection, can not
be used to differentiate acute respiratory infection from
pulmonary embolism in this clinical setting and has
therefore limited utility.
In conclusion, this study suggests that influenza infection
is not an important risk factor for pulmonary embolism.
Symptoms of influenza are non-specific and can be
present in patients with a pulmonary embolism. These
symptoms can therefore not be used to differentiate
between acute respiratory infection and pulmonary
embolism in this clinical setting.
Abbreviations
CFA = complement fixation assay; 95% CI = 95% confi-
dence interval; COPD = chronic obstructive pulmonary
disease; CVD = cardiovascular disease; ILI = influenza-like
illness; SD = standard deviation; VTE = venous tromboem-
bolism
Table 2: Association between influenza and pulmonary embolism.
Odds ratios (OR) and 95% confidence intervals (95% CI)
Crude OR (95% CI) Adjusted OR (95% CI)
Influenza A 0.22 (0.03–1.67) 0.22 (0.03–1.72)
Influenza-like illness 1.28 (0.75–2.18) 1.16 (0.67–2.01)
Odds ratios (OR) on the association between influenza A infection and influenza-like illness score and pulmonary embolism with corresponding 
95% confidence intervals (95% CI). Crude OR are adjusted for age, COPD (= chronic obstructive pulmonary disease) and asthma. We did not 
calculate the odds ratio for influenza B, because there were only few infected patients (0 in the case group, 3 in the control group).Publish with BioMed Central    and   every 
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